Y-mAbs Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Y-mAbs Therapeutics

06/11/2024 14:14

* Y-mAbs Therapeutics Inc  YMAB.OQ   YMAB.O  is expected
to show a
rise in quarterly revenue when it reports  results on November 8
for the period ending September 30 2024
    * The New York City-based  company is expected to report a
13.7% increase in revenue to $23.263 million from $20.45 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc
is for
a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is 21.50​, above​ its last closing price
of $15.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.13       -0.13      -0.21     Missed  -59.8
 Mar. 31 2024  -0.14       -0.14      -0.15     Missed  -10.5
 Jan. 1 0001   -0.20       -0.20      -0.02     Beat    90.1​
 Sep. 30 2023  -0.18       -0.19      -0.18     Beat    3.7
 ​​Jun.        -0.24                  -0.14             42.1
 30 2023                                                
 Mar. 31 2023  -0.32       -0.32      -0.15     Beat    52.9​
 Dec. 31 2022  -0.44       -0.46      0.03      Beat    106.6
 Sep. 30 2022  -0.71       -0.71      -0.63     Beat    11.3
 This summary was machine generated November 6 at 14:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)